STOCK TITAN

Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis

CRNX

Crinetics Pharmaceuticals (CRNX) last traded on August 31, 2026. A Form 15-12G filed on September 11, 2026 ends the SEC registration of its shares.

Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
25 252 sessions, August 29, 2025 to August 31, 2026
Largest daily move
+98.7% close of July 7, 2026
1-year change
+174.1% closing prices, August 29, 2025 to August 31, 2026
1-month change
+1.7% closing prices, July 31, 2026 to August 31, 2026

Company Description

Written before these shares stopped trading.

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is a global pharmaceutical company focused on the discovery, development, and commercialization of novel therapies for endocrine diseases and endocrine-related tumors. According to company disclosures, Crinetics’ research is rooted in patient needs and centers on targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.

The company’s lead product is PALSONIFY™ (paltusotine), described as the first once-daily, oral treatment approved by the U.S. Food and Drug Administration (FDA) for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. PALSONIFY is a selectively targeted somatostatin receptor type 2 (SST2) nonpeptide agonist. In addition to its approved acromegaly indication, paltusotine is in clinical development for carcinoid syndrome associated with neuroendocrine tumors, including evaluation in the pivotal Phase 3 CAREFNDR trial.

Beyond PALSONIFY, Crinetics reports a deep pipeline of more than ten disclosed programs aimed at a variety of endocrine and endocrine-related conditions. A key late-stage investigational candidate is atumelnant, a once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland. Atumelnant is in late-stage or Phase 3 clinical development for classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome, with clinical data showing reductions in CAH-related biomarkers such as androstenedione and 17-hydroxyprogesterone in Phase 2 studies.

Crinetics is also advancing CRN09682, an investigational, first-in-class, non-radioactive, nonpeptide drug conjugate (NDC) designed for the treatment of neuroendocrine tumors (NETs) and other SST2-expressing solid tumors. CRN09682 links a somatostatin receptor 2 agonist to the cytotoxic drug monomethyl auristatin E (MMAE) via a spacer and cleavable linker. The ligand component is designed to bind SST2 on tumor cells, internalize, and release MMAE within the cell after enzymatic cleavage, with the goal of concentrating cytotoxic activity in tumors while limiting systemic exposure. CRN09682 is being evaluated in the Phase 1/2 BRAVESST2 trial in patients with metastatic or locally advanced SST2-positive neuroendocrine tumors and other SST2-expressing solid tumors.

In addition to these advanced programs, Crinetics describes multiple discovery and preclinical efforts that extend its GPCR-focused approach. These include:

  • CRN12755, a thyroid-stimulating hormone receptor (TSHR) antagonist program for Graves’ disease, including Graves’ hyperthyroidism and Graves’ orbitopathy (thyroid eye disease).
  • CRN10329, a selective SST3 nonpeptide agonist for autosomal dominant polycystic kidney disease (ADPKD).
  • Additional discovery programs addressing conditions such as neuroendocrine tumors, Graves’ disease, polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.

Crinetics’ regulatory and clinical milestones highlight its transition from a clinical-stage company toward commercial operations. The company has reported that the FDA approved PALSONIFY for first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option, and that it has initiated and advanced pivotal trials such as the CALM-CAH Phase 3 study for atumelnant in classic CAH and the CAREFNDR Phase 3 trial for paltusotine in carcinoid syndrome. The company has also disclosed Orphan Drug Designation from the FDA for atumelnant in the treatment of classic CAH.

Crinetics’ pipeline and clinical programs are frequently featured in its research and development events, scientific conference presentations, and SEC filings. For example, the company has highlighted eight abstracts from its clinical development programs at the Endocrine Society’s ENDO meeting and has provided detailed R&D Day updates on early-stage assets such as CRN12755, CRN10329, and CRN09682, including preclinical data on biomarker changes, receptor expression, and anti-tumor activity in animal models.

From a corporate perspective, Crinetics trades on the Nasdaq Global Select Market under the ticker symbol CRNX. The company uses equity-based compensation, including stock options and restricted stock units granted under its 2021 Employment Inducement Incentive Award Plan, as a tool to recruit and retain non-executive employees, as disclosed in multiple inducement grant announcements made in accordance with Nasdaq Listing Rule 5635(c)(4). The company also accesses the capital markets through underwritten public offerings of common stock, with proceeds intended to support commercialization of PALSONIFY, research and development of product candidates, and other general corporate purposes.

Crinetics’ SEC filings provide additional context on its operations and governance. Current reports on Form 8-K have addressed topics such as FDA approval of PALSONIFY, financial results for specified reporting periods, research and development updates, and executive transitions. For instance, the company has reported a transition of its Chief Medical and Development Officer role and subsequent advisory engagement, illustrating how it manages leadership changes while maintaining continuity in regulatory and development strategy.

Overall, Crinetics Pharmaceuticals presents itself as a specialized pharmaceutical company within the biotechnology and life sciences ecosystem, with a focus on small-molecule GPCR-targeted therapies for complex endocrine and endocrine-related conditions. Its combination of an FDA-approved oral therapy for acromegaly, late-stage candidates for CAH and carcinoid syndrome, and a growing portfolio of discovery and preclinical programs positions the company as an active participant in the development of targeted treatments for rare and serious endocrine disorders.

Stock Performance

$84.95
No recent trading
Last close: August 31, 2026
+174.1%
1 year to August 31, 2026

Crinetics Pharmaceuticals (CRNX) closed at $84.95 on August 31, 2026. In the 12 months to August 31, 2026, the price gained 174.1%.

See what a $1,000 investment in CRNX would be worth today

Average down calculator for CRNX

CRNX Metrics & Rankings

Price returns through August 31, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Crinetics Pharmaceuticals has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include acquisition, earnings, earnings date, clinical trial. View all CRNX news →

Financial Highlights

Crinetics Pharmaceuticals generated $7.7M in revenue in FY2025, retaining a 86.0% gross margin, operating income reached -$516.8M, and net income was -$465.3M. Diluted earnings per share stood at -$4.95. The company generated -$377.9M in operating cash flow. The current ratio was 12.32, measuring current assets divided by current liabilities.

$7.7M
Revenue (FY2025)
-$465.3M
Net Income (FY2025)
-$377.9M
Operating Cash Flow

Upcoming Events

DEC
10
December 10, 2026 - December 10, 2029 Corporate

Stock options vesting schedule

25% of 39,575 options vest 2026-12-10; remaining vest monthly over next 36 months.
DEC
10
December 10, 2026 - December 10, 2029 Corporate

RSU vesting schedule

26,525 RSUs vest in four equal annual installments from 2026-12-10 through 2029-12-10.
YEAR
2027
2027 Marketing

Broader endocrine expansion begins

Crinetics will expand Everyday Advocacy to broader endocrine conditions starting 2027; steering committee to guide workshops.
JAN
10
January 10, 2027 Corporate

Options 25% vesting

25% of 37,575 options vest; subject to continued employment
JAN
10
January 10, 2027 - January 10, 2030 Corporate

Options monthly vesting period

Remaining 75% of 37,575 options vest monthly; exercise price $53.25
JAN
10
January 10, 2027 - January 10, 2030 Corporate

RSUs annual vesting

25% of 25,525 RSUs vest annually; subject to continued employment

Crinetics Pharmaceuticals has 6 upcoming scheduled events. The next event, "Stock options vesting schedule", is scheduled for December 10, 2026 (in 24 days). Investors can track these dates to stay informed about potential catalysts that may affect the CRNX stock price.

Short Interest History

Last 12 Months

Short interest in Crinetics Pharmaceuticals (CRNX) currently stands at 6.8 million shares, up 3.9% from the previous reporting period, representing 6.6% of the float. Since November 2025, short interest has decreased by 50.6%.

Days to Cover History

Last 12 Months

Days to cover for Crinetics Pharmaceuticals (CRNX) currently stands at 2.4 days, down 23.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 79.2%. Across the settlements charted above, it has ranged from 1.0 to 18.0 days.

CRNX Company Profile & Sector Positioning

Crinetics Pharmaceuticals (CRNX) operates in the Biotechnology industry within the broader Healthcare sector.

Investors comparing CRNX often look at related companies in the same sector, including Septerna, Inc. (SEPN), Protagonist Therapeutics, Inc (PTGX), Tango Therapeutics, Inc. (TNGX), Viridian Therapeutics, Inc. (VRDN), and MBX Biosciences, Inc. (MBX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CRNX's relative position within its industry.

Frequently Asked Questions

Crinetics Pharmaceuticals (CRNX) last traded on August 31, 2026. A Form 15-12G filed on September 11, 2026 ends the SEC registration of its shares.

Crinetics Pharmaceuticals (CRNX) has no recent trading. Its last close was $84.95 on August 31, 2026.

The FY2025 revenue of Crinetics Pharmaceuticals (CRNX) is $7.7M, from its most recent completed fiscal year.

The FY2025 net income of Crinetics Pharmaceuticals (CRNX) is -$465.3M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Crinetics Pharmaceuticals (CRNX) is -$4.95 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Crinetics Pharmaceuticals (CRNX) is -$377.9M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The gross profit margin of Crinetics Pharmaceuticals (CRNX) is 86.0% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Crinetics Pharmaceuticals (CRNX), current assets divided by current liabilities, was 12.32 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Crinetics Pharmaceuticals (CRNX) is $6.6M for FY2025, its most recent completed fiscal year.

The operating income of Crinetics Pharmaceuticals (CRNX) is -$516.8M for FY2025, its most recent completed fiscal year. Learn about operating income.